New possibilities for the treatment of systemic lupus erythematosus. How much does the effect cost?
Our previous study has shown that the new biologic disease-modifying antirheumatic drug (bDMARD) anifrolumab (AFM) can be considered as a cost-effective alternative to belimumab (BLM) in the treatment of systemic lupus erythematosus (SLE). Following a review by the Commission of the Ministry of Heal...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2025-02-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1699 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|